FDA Approved Peptides List 2026: Drugs & Pipeline

FDA Approved Peptides List 2026: Drugs & Pipeline. Current list of clinically approved peptide therapeutics for human use. Popular therapeutic peptides, indications, and new peptides on the market 2026. Key Takeaways Searching for a peptides FDA approved list? This complete guide covers ~130 approved peptide drugs plus 2024-2025 new approvals ~130 peptide drugs now FDA approved: Four new TIDES (peptides and oligonucleotides) received FDA approval in 2024 alone 2024-2025 new approvals: Yorvipath (hypoparathyroidism), Aqneursa (Niemann-Pick), Lumisight (breast cancer imaging), Forzinity (Barth syndrome) GLP-1 compounding restrictions: Tirzepatide and semaglutide compounding ended in early 2025 following shortage resolution 2026 pipeline: Retatrutide, CagriSema, and survodutide are in late-stage trials with potential approvals Research peptides remain distinct: Compounds like BPC-157, TB-500 , and Ipamorelin are NOT FDA approved Introduction: The Peptide Therapeutics Revolution If you're searching for a list of FDA approved peptide drugs , a comprehensive FDA approved injectable peptides list , or wondering which peptides are FDA approved for human use — this is the current list of clinically approved peptide therapeutics covering every approved compound with indications and manufacturer details. The number of FDA approved peptide drugs continues to grow. With approximately 130 peptide drugs now approved — including new peptides on the market in 2025 and popular therapeutic peptides entering late-stage trials — this is one of the most dynamic sectors in pharmaceuticals. What peptides just got FDA approved? Which are legal peptides? When will more peptides be FDA approved? This guide answers all of it. Peptide therapeutics offer unique advantages: high target specificity, lower immunogenicity than protein biologics, and the ability to mimic natural hormonal signaling. From metabolic disorders to rare genetic diseases, the FDA approved peptides list for 2026 represents one of the most dynamic sectors in modern pharmaceuticals. This is the complete clinically approved peptide therapeutics 2019-2026 reference — a full list of FDA approved peptides 2026 covering injectables, the expanding oral peptide drugs list, and every therapeutic category where peptide drugs are approved for human use. For exact-match searches, this is also a FDA approved peptide drugs list 2025 2026 , a list of FDA-approved peptides 2026 , and a list of FDA-approved therapeutic peptides . The table below prioritizes approved drug status, indication, and manufacturer rather than research-only peptide availability. If you are comparing FDA-approved peptide drugs against research-use-only vendor listings, start with our best grey market peptide vendors ranking so the regulatory distinction is clear before evaluating supplier claims. Get FDA-Approved Peptide Medications Now Several peptide-based treatment categories are available through current telehealth partner offers — no in-person visit required. GLP-1 receptor agonists like semaglutide and tirzepatide remain among the most prescribed peptide-based drugs in the world, while NAD+ and Sermorelin are commonly offered in longevity and recovery programs. Current Telehealth Offer GLP-1 Injections — Monthly Flexible Plan $285/mo Semaglutide and tirzepatide pathways through Yucca Health. Licensed-provider review and home delivery. Get Started → Current Telehealth Offer NAD+ — $192/mo Yucca Health longevity program for cellular energy and wellness support. Get Started → Current Telehealth Offer Sermorelin — $192/mo Yucca Health muscle recovery program for natural growth hormone support. Get Started → New FDA Approved Peptides (2024-2025) The past 18 months have seen significant additions to the official FDA approved peptides list, with several breakthrough therapies receiving regulatory clearance: 1. Palopegteriparatide (Yorvipath) — August 2024 The FDA approved palopegteriparatide as the first and only treatment for hypoparathyroidism in adults. This once-daily subcutaneous injection represents a therapeutic breakthrough for this ultra-rare endocrine disorder affecting approximately 37 per 100,000 individuals. Mechanism: Pegylated prodrug of PTH (1-34) with sustained release over 7 days Innovation: Mimics natural parathyroid hormone action without requiring high-dose calcium supplements Clinical Impact: Significantly reduces urinary calcium loss and improves quality of life compared to conventional therapy 2. Levacetylleucine (Aqneursa) — September 2024 Approved for treating neurological manifestations of Niemann-Pick disease type C (NPC) , this modified amino acid therapy addresses a previously untreatable rare genetic disorder characterized by cholesterol trafficking dysfunction. Patient Population: Adults and pediatric patients weighing ≥15 kg Administration: Oral suspension Clinical Benefit: Improved neurologic status and mitochondrial energy metabolism in Phase 3 trials 3. Pegulicianine (Lumisight) — 2024 This diagnostic peptide agent functions as an intraoperative imaging adjunct to detect cancerous tissue within lumpectomy cavities during breast cancer surgery. 4. Elamipretide (Forzinity) — 2025 The most recent addition to the FDA approved peptides list, elamipretide received approval in 2025 for Barth syndrome (BTHS) , a rare X-linked genetic disorder affecting males. For researchers tracking elamipretide FDA approval status , the compound received full approval in 2025 following successful Phase 3 trials demonstrating improved muscle strength in Barth syndrome patients. For the full regulatory timeline, see our elamipretide FDA approval status 2026 guide. Structure: H-D-Arg-2,6-diMe-L-Tyr-L-Lys-L-Phe-NH2 (C-terminal amidation) Indication: First therapy approved to improve muscle strength in BTHS patients Mechanism: Targets mitochondrial dysfunction underlying skeletal muscle weakness and cardiomyopathy FDA Approved Peptides by Therapeutic Category Metabolic & Endocrine Peptides (GLP-1 & GIP) The metabolic peptide sector dominates current prescribing patterns, with the GLP-1 receptor agonist class leading unprecedented demand: Peptide (Brand) Indication FDA Approval Manufacturer Semaglutide (Ozempic/Wegovy) Type 2 diabetes, Weight management, CVD risk 2017/2021 Novo Nordisk Tirzepatide (Mounjaro/Zepbound) Type 2 diabetes, Obesity 2022/2023 Eli Lilly Liraglutide (Victoza/Saxenda) Type 2 diabetes, Weight management 2010/2014 Novo Nordisk Dulaglutide (Trulicity) Type 2 diabetes, CVD risk reduction 2014 Eli Lilly Exenatide (Byetta/Bydureon) Type 2 diabetes 2005 AstraZeneca Lixisenatide (Adlyxin) Type 2 diabetes 2016 Sanofi Pramlintide (Symlin) Type 1 & 2 diabetes adjunct 2005 N/A 2026 Pipeline Update: Tirzepatide is under FDA review for pediatric indications with decisions expected in 2026, while semaglutide 7.2 mg and combination therapies (cagrilintide + semaglutide) are advancing through late-stage development. The tirzepatide FDA approval status continues to expand — originally approved for diabetes in 2022, it gained obesity indication (Zepbound) in 2023. For researchers asking about FDA approved peptides for weight loss , tirzepatide and semaglutide remain the only GLP-1 agonists with official obesity indications. Cancer & Oncology Peptides Peptide (Brand) Indication Mechanism Approval Degarelix (Firmagon) Advanced prostate cancer GnRH antagonist 2008 Carfilzomib (Kyprolis) Multiple myeloma Proteasome inhibitor 2012 Pegulicianine (Lumisight) Breast cancer imaging Intraoperative fluorescence 2024 Hormonal & Replacement Therapies Peptide (Brand) Indication Route Key Features Palopegteriparatide (Yorvipath) Hypoparathyroidism SC Once-weekly injection, orphan drug status Teriparatide (Forteo/Bonsity) Osteoporosis SC PTH analog for bone formation Forteo (teriparatide) remains the gold standard for anabolic bone therapy, with generic versions (Bonsity) now available following patent expiration. Peptide (Brand) Indication Route Key Features Sermorelin (Geref) Growth hormone deficiency SC GHRH analog Tesamorelin (Egrifta) HIV-associated lipodystrophy SC Reduces excess abdominal fat — see full Tesamorelin FDA status guide or compare Tesamorelin 10mg research peptide availability Mecasermin (Increlex) Severe primary IGF-1 deficiency SC IGF-1 replacement Corticorelin (Acthrel) Pituitary-adrenal axis testing IV Diagnostic ACTH analog GI & Motility Peptides Linaclotide (Linzess/Constella): Guanylate cyclase-C agonist for IBS-C and chronic constipation (2012) Plecanatide (Trulance): Similar mechanism for CIC and IBS-C (2017) Lubiprostone (Amitiza): Chloride channel activator for CIC (2006) Cardiovascular & Vasoactive Peptides Angiotensin II (Giapreza): Vasoconstrictor for distributive shock (2017) Vasopressin (Vasostrict): Vasodilatory shock treatment (2014) Eptifibatide (Integrilin): GP IIb/IIIa inhibitor for ACS (1998) Bivalirudin (Angiomax): Anticoagulant for PCI (2000) Natural & Endogenous Peptides The FDA has approved approximately 10 natural peptide analogs that mimic endogenous hormones: Insulin (1923) — The first approved peptide therapeutic Corticotropin/ACTH (1952) — Multiple sclerosis and infantile spasms Oxytocin (1996) — Uterine contraction and lactation support Glucagon (1998) — Severe hypoglycemia rescue Secretin (2002) — Diagnostic aid for pancreatic function Calcitonin (2005) — Hypercalcemia and osteoporosis Oral vs Injectable FDA Approved Peptide Drugs Most FDA approved peptide drugs are injectable because peptide chains are usually broken down in the gastrointestinal tract before they can reach systemic circulation. That is why the FDA approved injectable peptide drugs list includes insulin products, GLP-1 receptor agonists such as semaglutide and tirzepatide, PTH analogs such as teriparatide and palopegteriparatide, tesamorelin, glucagon rescue products, and several diagnostic or oncology-related peptide agents. The oral peptide drugs list is much shorter but clinically important. Rybelsus is oral semaglutide for type 2 diabetes, while linaclotide (Linzess) and plecanatide (Trulance) are oral peptide agonists used for constipation-related GI indications. These oral examples are exceptions rather than the rule, and they use either local gut activity or specialized formulation strategies rather than the standard subcutaneous delivery used by many metabolic peptide drugs. Critical Regulatory Updates (2025-2026) GLP-1 Shortage Resolution & Compounding Restrictions The FDA made significant policy changes in 2024-2025 regarding compounded peptide medications: Tirzepatide (Mounjaro/Zepbound): Removed from FDA shortage list: October 2, 2024 Compounding deadline for 503A pharmacies: February 18, 2025 Compounding deadline for 503B facilities: March 19, 2025 Semaglutide (Ozempic/Wegovy): Shortage status resolved: February 21, 2025 Enforcement discretion ended for 503A compounders: April 22, 2025 503B compounders must cease: May 22, 2025 These changes mean that as of 2026, patients will require prescriptions for FDA-approved brand-name versions rather than compounded alternatives. Peptide Compounding Advisory Committee (PCAC) Reviews Following legal settlements in September 2024, the FDA agreed to submit several investigational peptides for public PCAC review rather than immediate banning: CJC-1295 (Growth hormone secretagogue) Thymosin Alpha-1 (Immunomodulatory) Ipamorelin (Growth hormone releasing peptide) AOD-9604 (HGH fragment) These peptides remain unapproved for human use pending formal FDA evaluation through proper notice-and-comment rulemaking. For mainstream media coverage of these research peptides, see our Joe Rogan peptides analysis . For a detailed comparison of GH secretagogues, see our CJC-1295 vs Ipamorelin guide . The Future: FDA Approved Peptides 2026 & Beyond Late-Stage Pipeline (Expected Decisions 2025-2026) The following peptide therapeutics are undergoing FDA review or Phase 3 trials with potential 2026 approvals: Retatrutide (Eli Lilly) — the retatrutide approval status 2026 covers this Triple G (GIP/GLP-1/Glucagon) receptor agonist for obesity Cagrilintide + Semaglutide (CagriSema) — the cagrilintide FDA approval status tracks this Novo Nordisk combination therapy for obesity Survodutide — The survodutide FDA approval status 2026 shows this dual glucagon/GLP-1 receptor agonist (Zealand/Boehringer Ingelheim) is in Phase 3 trials for obesity and MASH (metabolic dysfunction-associated steatohepatitis). Researchers following peptide clinical trial news should watch for 2026 NDA submission. Eneboparatide — Long-acting PTH analog for hypoparathyroidism (Phase 3) Zotleucel (TissueGene) — Cell therapy involving peptide factors for knee osteoarthritis For more details on retatrutide's approval timeline, see our dedicated article: Is Retatrutide FDA Approved? Technological Innovations The 2026 FDA approved peptides list will likely feature enhanced delivery technologies: GalNAc conjugation for liver-targeted delivery (currently used in oligonucleotides, expanding to peptides) Pegylation for extended half-life (exemplified by palopegteriparatide's 60-hour half-life) Oral peptide formulations overcoming bioavailability barriers Prodrug strategies improving tissue-specific activation Safety Considerations & Black Box Warnings Clinicians prescribing from the FDA approved peptides list should note specific safety profiles: Staying current with FDA peptide warning news is essential for clinicians. Recent safety communications have addressed thyroid cancer risks with GLP-1 agonists and injection site reactions with newer subcutaneous peptides. Palopegteriparatide (Yorvipath): Potential osteosarcoma risk (observed in animal studies) Requires monitoring of calcium and vitamin D levels Injection site reactions and vasodilatory symptoms common GLP-1 Receptor Agonists: Boxed warning for thyroid C-cell tumors (rodent studies) Contraindicated in personal/family history of medullary thyroid carcinoma Risk of pancreatitis and gallbladder disease GI adverse effects (nausea, vomiting, diarrhea) Elamipretide (Forzinity): First-in-class mitochondrial therapy requiring specialized monitoring Drug interactions with CYP pathways under investigation Research Peptides vs. FDA Approved Peptides It's essential to distinguish between FDA-approved therapeutics and research-only compounds. The following peptides are NOT FDA approved and remain research tools: Researchers frequently search for FDA status peptides BPC-157 TB-5 (00) information — including the TB-500 FDA approval status . As shown in the table below, neither compound has FDA approval or active clinical trial programs in the USA. Other mitochondrial-derived peptides like MOTS-c are also unapproved — for a deep dive into where that compound stands in the regulatory pipeline, see our MOTS-c clinical trials status 2026 breakdown. Compound FDA Status Research Focus BPC-157 Not approved Tissue healing research TB-500 Not approved Wound healing research Ipamorelin Not approved GH secretagogue research CJC-1295 Not approved (CJC-1295 FDA approval status: no active clinical trials) GHRH analog research PT-141 Not approved (PT-141 FDA approval status: research only; note: bremelanotide/Vyleesi IS approved) Melanocortin research Retatrutide Not approved (in trials) Triple receptor agonist research For laboratory research with these compounds, browse our research peptide catalog with third-party COAs. For detailed research on anti-inflammatory peptides like KPV, see our comprehensive KPV peptide guide . Need help with reconstitution math? Use our free Peptide Calculator to determine concentration and dosage. For a detailed comparison of tissue repair peptides, see our BPC-157 vs TB-500 research guide . Wondering about prescription requirements? See our guide: Do You Need a Prescription for Peptides? Frequently Asked Questions: Peptide FDA Status BPC-157 FDA Approval Status January 2026 The BPC-157 FDA approval status January 2026 remains unchanged: BPC-157 is NOT FDA approved. There are no active clinical trials for BPC-157 in the USA, and researchers searching for BPC-157 FDA approval status or clinical trials pipeline USA will find no ongoing human studies registered with ClinicalTrials.gov. BPC-157 remains a research-only compound without a clear regulatory pathway. For the full 2026 regulatory picture — including the RFK Jr Category 1 reclassification announcement and the July 23-24 Pharmacy Compounding Advisory Committee review — see our dedicated BPC-157 FDA approval status 2026 guide. GHK-Cu FDA Approval Status For researchers asking about GHK-Cu FDA approval status , this copper-binding tripeptide is NOT FDA approved for therapeutic use. While GHK-Cu appears in some topical cosmetic formulations, it has no drug approval and is classified as a research compound when sold in injectable form. For the complete regulatory breakdown, see our GHK-Cu FDA approval status 2026 guide. FDA Approved Peptides for Weight Loss The official FDA approved peptides for weight loss are limited to GLP-1 receptor agonists with obesity indications: Wegovy (semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide). Research compounds like AOD-9604 and other "fat loss peptides" are NOT FDA approved for weight management. Conclusion This list of FDA approved peptide therapeutics represents over a century of therapeutic innovation, from the isolation of insulin in 1921 to the sophisticated pegylated prodrugs and dual agonists of today. With approximately 130 approved peptide therapeutics currently available and a robust pipeline including next-generation metabolic agents and rare disease treatments, peptides continue to fill critical therapeutic gaps. For healthcare providers, staying current with rapid regulatory changes — particularly regarding FDA bulk drug substances list updates, compounding restrictions, and shortage resolutions — is essential for maintaining patient access to these vital therapies. For researchers and pharmaceutical developers, the FDA's increasing comfort with novel peptide modifications (pegylation, non-natural amino acids, conjugation technologies) signals continued expansion of this drug class through 2026 and beyond. Key Takeaway: The peptide therapeutics market has evolved from simple hormonal replacements to complex designer molecules capable of addressing previously untreatable conditions like Niemann-Pick disease type C and Barth syndrome, positioning peptides as one of the most valuable tools in modern precision medicine. Frequently Asked Questions What peptides are FDA approved? Approximately 130 peptide drugs are currently FDA approved, including insulin, GLP-1 agonists (semaglutide, tirzepatide, liraglutide), PTH analogs (teriparatide, palopegteriparatide), and various diagnostic and therapeutic peptides across oncology, endocrinology, and cardiovascular medicine. Is semaglutide FDA approved? Yes. Semaglutide is FDA approved under brand names Ozempic (2017, type 2 diabetes), Wegovy (2021, weight management), and Rybelsus (2019, oral formulation for diabetes). Is tirzepatide FDA approved? Yes. Tirzepatide is FDA approved under brand names Mounjaro (2022, type 2 diabetes) and Zepbound (2023, chronic weight management). For dose math on compounded research vials, see our tirzepatide unit converter . Is retatrutide FDA approved? No. Retatrutide is currently in Phase 3 clinical trials with Eli Lilly. FDA approval is expected in 2026-2027 pending trial results. See our retatrutide approval status article for the latest updates. Is BPC-157 FDA approved? No. BPC-157 is not FDA approved for any human therapeutic use. It remains a research compound sold for laboratory and investigational purposes only — track the latest BPC-157 FDA approval status for RFK Jr Category 1 reclassification updates. What new peptides were approved in 2024-2025? Recent FDA approvals include palopegteriparatide (Yorvipath) for hypoparathyroidism, levacetylleucine (Aqneursa) for Niemann-Pick disease, pegulicianine (Lumisight) for breast cancer imaging, and elamipretide (Forzinity) for Barth syndrome. References U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs database. accessdata.fda.gov U.S. Food and Drug Administration. Novel Drug Approvals. fda.gov U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. FDA Label U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. FDA Label U.S. Food and Drug Administration. Egrifta (tesamorelin) prescribing information. FDA Label ClinicalTrials.gov. National Library of Medicine clinical trials database. clinicaltrials.gov U.S. Food and Drug Administration. Forzinity (elamipretide) approval announcement. fda.gov news Related reading: Investigational Peptide Drugs: Diabetes & Obesity Review PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.